In this webinar, Touchlight’s Elena Stoyanova, PhD introduces the company’s innovative DNA manufacturing technologies, focusing on their proprietary dbDNA™ (Doggybone DNA) and the newly developed mbDNA™ (MegaBulb DNA ). She explains how dbDNA, a minimal, enzymatically amplified linear DNA vector, offers advantages over traditional plasmid DNA, including higher purity, faster production, and improved safety. The session also highlights mbDNA, a novel circular single-stranded DNA template designed to overcome limitations in gene editing by enhancing stability, manufacturability, and knock-in efficiency for HDR applications.

Download the webinar to learn:

• How dbDNA and mbDNA technologies address key challenges in gene therapy and gene editing.
• Understand the structural and functional advantages of enzymatically produced DNA over traditional plasmid and viral vectors.
•  Insights into scalable, non-viral DNA manufacturing solutions for next-generation therapeutics.